A Randomised, Double Blind, Placebo Controlled Study to Assess the Effects of Ranitidine on the Survival of Patients with Gastric Cancer
Completed
- Conditions
- Gastric CancerCancerGastric
- Registration Number
- ISRCTN41155448
- Lead Sponsor
- Glaxo Wellcome (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Aged <18 years
2. Gastric cancer proven by histology and endoscopy or barium meal
3. Patients selected for laparotomy must commence intravenous treatment with study drug at the time of induction of anaesthesia
4. Adequate renal function
5. No previous resection for gastric cancer
6. No other prior or concurrent malignancy
7. No treatment with systemic steroids, hormones or other know immunomodulating drugs within the last 7 days prior to the start of the study period
8. No medical contraindications to study treatments
Exclusion Criteria
Not provided at time of registration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ot provided at time of registration
- Secondary Outcome Measures
Name Time Method ot provided at time of registration